Reading this on a mobile device? Try our optimized mobile version here:

April 20, 2012
BIO has teamed up with FedEx to offer member companies discounts of up to 35% off select FedEx Express, FedEx Ground and FedEx Home Delivery services through the BIO Business Solutions cost-savings program. Learn more.

The news summaries appearing in BIO SmartBrief are based on original information from news organizations and are produced by SmartBrief, Inc., an independent e-mail newsletter publisher. The information is not compiled or summarized by BIO. Questions and comments should be directed to SmartBrief at

  Today's Top Story 
  • HGS turns down GSK's $2.6 billion bid
    Human Genome Sciences rejected GlaxoSmithKline's $2.6 billion acquisition bid, saying the offer undervalues the biotech firm. GSK CEO Andrew Witty said the drugmaker is disappointed and thinks the offer "is in the best interest of shareholders of both companies." The firms work together on lupus drug Benlysta and two late-stage drug candidates for diabetes and artery hardening. Bloomberg Businessweek (4/19), Google/The Associated Press (4/19) LinkedInFacebookTwitterEmail this Story
EvaluatePharma® ‘s new affordable, one-stop service EP Clinical Trials offers you a confident new world of clinical trial intelligence that's exceptionally faster than doing it yourself. Find out more and request a demo
  Health Care & Policy 
  • Senate bill aims for FDA reform
    Sens. Tom Coburn, R-Okla., and Richard Burr, R-N.C., introduced a bill aimed at improving the FDA's internal management as well as accountability in regulating drugs and medical devices. The Patients' FDA Act would relax restrictions on companies' ties with physicians and speed up product-approval review. The proposal is meant to be part of the Prescription Drug and User Fee Act reauthorization. Forbes/The Apothecary blog (4/18) LinkedInFacebookTwitterEmail this Story
  • Congress shows interest in increasing NIH budget
    Two bipartisan "Dear Colleague" letters circulating in Congress have garnered widespread support for increasing NIH funding, which remains flat in the budget proposal given to Congress by President Barack Obama. The House letter, which has garnered 153 signatures, calls for a 4% increase, or $32 billion. The Senate letter, which does not specify a funding level, has been supported by 47 senators. Genetic Engineering & Biotechnology News (4/18) LinkedInFacebookTwitterEmail this Story
  • Breast cancer categorization could help tailor treatment
    An analysis of 997 tumors resulted in 10 distinct breast cancer categories, ranging from easily treated to very aggressive, which may help precisely target therapies and prevent unnecessarily toxic treatments in patients, researchers reported in the journal Nature. "This is going to have a huge impact on the way we think about breast cancer. Together with other data coming out in the next few months, I think the whole landscape of research, discovery and treatment is going to change," said Harvard Medical School professor Raju Kucherlapati, who was not part of the study. Los Angeles Times (tiered subscription model) (4/19), BBC (4/18) LinkedInFacebookTwitterEmail this Story
  • Hepatitis C drug candidates yield positive results in trials
    All hepatitis C patients treated with Gilead Sciences' GS-7977 plus Bristol-Myers Squibb's daclatasvir attained a sustained virologic response four weeks after the treatment, a clinical trial found. In another study, 88% of 25 treatment-naive patients with genotype 1 hepatitis C who received Gilead's GS-7977 and ribavirin achieved SVR 4 after 12 weeks of treatment. The results boost the possibilities for an interferon-free, all-oral regimen for hepatitis C. The Wall Street Journal/Dow Jones Newswires (4/19) LinkedInFacebookTwitterEmail this Story
  • Researchers use stem cells to regrow hair in bald mice
    Japanese researchers used epithelial stem cells and mesenchymal cells to engineer hair follicles that grew like normal hair when implanted in bald mice. The development may help in the regeneration of organs such as salivary glands, which grow in the same way as hair in their early development, a researcher said. The findings were published in the journal Nature Communications. Science News (4/18) LinkedInFacebookTwitterEmail this Story
7 keys: Put real-world evidence into action
Life sciences organizations need to know how their therapies work in the real world once clinical trials end. And these seven key components to standardizing real-world data and analytics platforms are how they get started. Read the paper, Institutionalizing Real World Evidence.
  Company & Financial News 
  Featured Content 

  Food & Agriculture 
  • WSU opens lab for plant breeding
    Washington State University opened a phenomics laboratory to help breeders screen plants for difficult-to-find traits such as disease resistance. The $250,000 laboratory will help breeders discover quickly which plants don't have desired traits, WSU assistant professor Michael Neff said. Capital Press Agriculture Weekly (4/19) LinkedInFacebookTwitterEmail this Story
  Industrial & Environmental 
  • Study: Light-sensitive enzyme can lower cost of biofuels
    Researchers at the Oak Ridge National Laboratory in Tennessee found that exposure to certain light wavelengths can increase the productivity of the enzyme Candida antarctica lipase B by as much as 30 times, potentially lowering the cost of biofuels and other biobased products. The study shows that "introducing a compound that undergoes a light-inducible conformational change onto the surface of the protein could be used to manipulate enzyme reaction," said lead researcher Pratul Agarwal. (4/18) LinkedInFacebookTwitterEmail this Story

Interested in learning more about advertising in BIO SmartBrief? Contact Meryl Harold at (202) 407-7828 or 

  News from BIO 
  • BIOtechNOW
    BIOtechNOW is the first in a number of new products from BIO intended to enhance our communications with the biotech community -- not only with our members, but with other stakeholders as well. This e-newsletter, combined with its website, serves as our flagship in that effort. BIOtechNOW will offer original content that emphasizes the business needs of the industry; highlight BIO's advocacy efforts; and provide a portal to all BIO activities and events. Most importantly, it will spotlight for those outside the industry the value of biotechnology. Sign up for the BIOtechNOW e-newsletter. LinkedInFacebookTwitterEmail this Story
Learn more about BIO ->Conferences  |  Join BIO  |  Media  |  Issues  |  Industry

Avoid popularity; it has many snares, and no real benefit."
--William Penn,
British statesman and philosopher

LinkedInFacebookTwitterEmail this Story

Subscriber Tools
Print friendly format | Web version | Search past news | Archive | Privacy policy

Account Director:  Meryl Harold (202) 407-7828
A powerful website for SmartBrief readers including:
 Recent BIO SmartBrief Issues:   Lead Editor:  Tom Parks
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2012 SmartBrief, Inc.® Legal Information